1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
2. The 10 × 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50:1081–3.
3. Nordberg P, Monnet DL, Cars O. Antibacterial drug resistance [priority medicines for Europe and the world, a public health approach to innovation]; 2004. http://soapimg.icecube.snowfall.se/stopresistance/Priority_Medicine_Antibacterial_background_docs_final.pdf (Accessed 27 Jan 2013).
4. The bacterial challenge: time to react. European Centre for Disease Prevention and Control/European Medicines Agency Joint Technical Report; 2009. http://www.emea.europa.eu/pdfs/human/antimicrobial_resistance/EMEA-576176-2009.pdf (Accessed 27 Jan 2013).
5. TEFLARO® (ceftaroline fosamil) [prescribing information]. St. Louis: Forest Pharmaceuticals, Inc.; 2012.